ExPEC9V

BIOLOGICAL2 trials

Sponsors

Janssen Research & Development, LLC

Conditions

Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention

Phase 3

A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years

CompletedNCT04899336

Janssen Research & Development, LLCInvasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention

Start: 2021-06-30End: 2025-08-27Updated: 2026-07-06

A Study of 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older

CompletedNCT06134804

Janssen Research & Development, LLCInvasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention

Start: 2023-10-24End: 2024-07-26Updated: 2026-04-03

Related Papers

Development and validation of a high-throughput agglutination assay for O-serogrouping clinical <i>Escherichia coli</i> isolates.

2026-08-21

Immunogenicity and Safety of the ExPEC9V Escherichia coli Vaccine Co-Administered with a High-Dose Influenza Vaccine in Older Adults: A Placebo-Controlled, Randomized, Phase 3 Study

Vaccines2026-01-30

A randomized phase 1/2a trial of ExPEC10V vaccine in adults with a history of UTI

npj Vaccines2024-06-1413 citations

Clinical presentation and antimicrobial resistance of invasive Escherichia coli disease in hospitalized older adults: a prospective multinational observational study.

2024-01-255 citations

Feasibility of tracking invasive Escherichia coli disease among older adults in a community setting: A prospective observational study

European Journal of Clinical Microbiology & Infectious Diseases2024-01-183 citations

Safety, Reactogenicity, Immunogenicity, and Dose Selection of 10-Valent Extraintestinal Pathogenic <i>Escherichia coli</i> Bioconjugate Vaccine (VAC52416) in Adults Aged 60–85 Years in a Randomized, Multicenter, Interventional, First-in-Human, Phase 1/2a Study

Open Forum Infectious Diseases2023-08-0126 citations

235. Tracking Invasive Extraintestinal Pathogenic Escherichia coli Disease in Older Adults in a Community-Based Clinical Trial Setting

Open Forum Infectious Diseases2022-12-01